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exon skipping has proven effective for reframingDMDmRNA,
rescuing dystrophin expression, and slowing disease progres-
sion in animal models. In humans with Duchenne muscular
dystrophy treated with AOs, low levels of dystrophin have
been induced, and modest slowing of disease progression has
been observed, highlighting the need for improved efficiency
of human skipping drugs. Here, we demonstrate that dantro-
lene and Rycals S107 and ARM210 potentiate AO-mediated
exon skipping of exon 44 or exon 45 in patient-derived myo-
tube cultures with appropriate mutations. Further, dantrolene
is shown to boost AO-mediated exon skipping in patient-
derived, induced cardiomyocyte cultures. Our findings further
validate the ryanodine receptors (RyR) as the likely target
responsible for exon skip boosting and demonstrate potential
applicability beyond exon 51 skipping. These data provide pre-
clinical support of dantrolene trial as an adjuvant to AO-medi-
ated exon-skipping therapy in humans and identify a novel
Rycal, ARM210, for development as a potential exon-skipping
booster. Further, they highlight the value of mutation-specific
DMD culture models for basic discovery, preclinical drug
screening and translation of personalized genetic medicines.Received 1 March 2019; accepted 12 September 2019;
https://doi.org/10.1016/j.omtn.2019.09.020.
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Duchenne muscular dystrophy (DMD) is a lethal genetic disease of
childhood, affecting 1/5,000 male births1 and is caused by mutations
in the DMD gene. The DMD gene encodes the dystrophin protein,
essential for the health of skeletal and heart muscle. Dystrophin is in-
tegral to the function of dystrophin-associated glycoprotein complex
(DGC), which provides structural support and membrane stability
during muscle contraction by linking the actin cytoskeleton to the
extracellular matrix.2 Additionally, dystrophin controls asymmetric
division in muscle stem cells, impacting stem cell renewal and
myogenic fate determination during muscle repair.3,4 Without func-
tional dystrophin, defects in sarcolemmal membrane stabilization
lead to progressive muscle damage, while stem cell defects limit the580 Molecular Therapy: Nucleic Acids Vol. 18 December 2019 ª 2019
This is an open access article under the CC BY-NC-ND license (httpefficiency of regeneration. Progressive muscle weakness leads to loss
of virtually all muscle function, respiratory and cardiac failure, and
premature death between ages 20 and 30.5
Most DMD mutations result from large frameshifting deletions
(65%),6 leading to complete absence of dystrophin protein expres-
sion and DMD. A milder phenotype, referred to as Becker muscular
dystrophy (BMD), typically results from in-frame deletions that lead
to the production of a partially functional dystrophin protein with an
internal deletion. “Exon skipping” is a therapeutic strategy that uses
antisense oligonucleotides (AOs) to bypass one or more exons in
the DMD pre-mRNA in order to restore reading frame and rescue
expression of a partially functional dystrophin protein. Exon-skip-
ping AOs have successfully restored the mRNA reading frame and
rescued dystrophin expression in DMD and animal models of
DMD.7–14 Initial human exon-skipping studies focused on the tar-
geted skipping of exons 51, 53, 45, 44, and 8, since these are predicted
to rescue the most commonly occurring human DMDmutations and
because mild phenotypes are associated with some naturally occur-
ring in-frame deletions in these regions.13,15,16
Eteplirsen, a morpholino AO targeting exon 51 for skipping, recently
received FDA accelerated approval based on the statistically signifi-
cant induction of dystrophin expression as a surrogate biomarker.17,18
However, only low levels of dystrophin induction (< 1% of typical
expression in skeletal muscle) have been observed so far in treated pa-
tients. While there is evidence that this low level of dystrophinThe Author(s).
://creativecommons.org/licenses/by-nc-nd/4.0/).
www.moleculartherapy.orginduction slowed progression of disease, as measured by 6-min walk
distance (6MWD), age at loss of ambulation (LOA), and forced vital
capacity (FVC), pulmonary function changes relative to external
DMD controls,18 it is likely that higher levels of dystrophin induction
would be more therapeutically relevant. Thus, identification of agents
capable of improving the efficacy of AO-mediated exon skipping are
of great interest and hold the potential to further increase dystrophin
levels in skeletal muscles and have a concomitant greater functional
benefit.
Dantrolene is an FDA-approved drug primarily used for the treatment
of malignant hyperthermia, neuroleptic malignant syndrome, and
spasticity.19 We previously published that dantrolene boosts DMD
AO-mediated exon 51 skipping in human DMD patient-derived fibro-
blasts, which were directly reprogrammed to myotubes through
myogenic differentiation 1 (Myod1) induction (induced directly re-
programmedmyotubes, termed iDRM).20 Further, systemic codelivery
of dantrolene was able to increase AO-mediated exon 23 skipping and
dystrophin protein rescue in mdx mice.20,21 However, it remains un-
clear whether dantrolene is able to increase the amount of dystrophin
produced when used in combination with AO targeting other exons
and how it functions to promote skipping.
Dantrolene can directly bind the Ryanodine receptors (RyR), which
controls Ca+-regulated muscle contraction.19 Since, like dantrolene,
ryanodine and Rycals S107 also increased exon skipping, we hypoth-
esize that dantrolene targets the RyR to potentiate exon skipping.
Using cultured myotubes generated from DMD patient-derived
inducible directly reprogrammable myotubes (iDRMs) and patient-
derived induced pluripotent stem cells (iPSCs), we investigated
exon 45 and exon 44 skipping and demonstrate that dantrolene as
well as Rycals S107 and ARM210 (a proprietary Rycal, ARMGO
Pharma) can each boost AO-directed skipping in culture. Finally,
DMD patient-derived iPSCs were differentiated into cardiomyocytes,
and dantrolene was shown to boost AO-mediated exon skipping of
exon 45. These findings serve to further elucidate the applicability
and mechanism of RyR modulators as boosters of AO-mediated
exon skipping in DMD.
RESULTS
Dantrolene Boosts AO-Mediated DMD Exon 45 and Exon 44
Skipping in Patient-Derived Myotube Cultures Amenable to
Rescue by Reframing
To determine if dantrolene increases AO-mediated exon skipping
of clinically relevant DMD mutations, we created cell culture
models from patients potentially amenable to exon 45 skipping (Cen-
ter for Duchenne Muscular Dystrophy 10003-CDMD1003, deletion
of exons 46–51; and CDMD1006, deletion of exons 46–47) or exon
44 skipping (CDMD1015, deletion of exon 45)22,23 (Figure 1).
Comparative genomic hybridization confirmed the expected DMD
mutations in primary fibroblasts (Figure 1A). RyR1 and RyR2
expression were determined by RT-PCR in DMD patient fibroblast
directly reprogrammed to skeletal muscle myotubes (iDRMs) or first
to iPSCs (Figures 1B and 1C) that are subsequently differentiated tocardiomyocytes. Consistent with their known expression patterns,
DMD iDRM- and iPSC-derived myotubes express RyR1, but not
RyR2, whereas iPSC-derived cardiomyocyte cultures predominantly
express RyR2. The findings validate our reprogramming and differ-
entiation schemes and demonstrate that RyRs, known dantrolene
targets, are appropriately expressed in these model systems (Figures
1B and 1C). Figure 1D provides a schematic indicating theDMDmu-
tations present in each cell model used in our studies and the primers
used for detecting mRNA lacking the potentially skipped exon that
would restore the reading frame if skipped (Figure 1D).
First, we tested the ability of dantrolene to boost exon 45 (iDRM
CDMD1003; Figure 2A) or 44 (iDRM 1015; Figure 2B) skipping in
iDRM-derived cultured myotubes. As shown in Figure 2, treatment
with AO induces targeted exon (exon 45 or exon 44) exclusion and
generation of a larger portion of skipped mRNA. Addition of dantro-
lene in combination with the appropriate AO increases the level of
skipped mRNA relative to AO alone in both exon 44 and exon 45
skip-amenable DMD cell models (Figure 2).
Rycals S107 and ARM210 Boost AO-Directed Exon 44 and 45
Skipping
Next, we tested the Rycals S107 and ARM210 for their ability to boost
AO-directed exon 45 or 44 skipping. We previously demonstrated
that Rycal S107 could potentiate AO-directed exon skipping in iDRMs
carrying a DMD mutation amenable to reframing by exon 51
skipping.20 ARM210 is a novel Rycal currently under development as
a potential standalone treatment targeting calcium defects that may
contribute to disease pathogenesis inDMDandwhich improvesmuscle
strength and muscle histology inmdxmice.24 Here, we demonstrate in
CDMD1003 iDRM- and iPSC-derived myotube cultures, treatment
with AO alone induces targeted exon 45-skipped mRNA (Figures 3A
and 3B). TreatmentswithAO/dantrolene,AO/Rycal S107, orAO/Rycal
ARM210 combinations each boost exon 45 skipping relative to AO
alone.Combination therapy similarly boosts dystrophin protein expres-
sion measure using in skeletal muscle cultures derived from
CDMD1003 iPSC detected using immunofluorescence (Figure 3C).
Similarly, dantrolene and Rycals S107 and ARM210 also boost AO-tar-
geted exon 44 skipping inCDMD1015 iDRMpatient-derivedmyotubes
(Figure 4A). Immunofluorescence staining for alpha-actinin demon-
strated striations in mature muscle cultures treated with AO alone or
in combination with dantrolene or Rycal ARM210 (Figure 4B).
To determine if the enhanced mRNA skipping in CDMD1015 was
translated into enhanced dystrophin protein rescue, we stained myo-
tube cultures with antibody specific for dystrophin. After iDRM
CDMD1015 differentiation, myotubes do not express dystrophin,
consistent with the out-of-frame DMD mutation (Figure 5, upper
panel). Low levels of dystrophin staining can be detected in some my-
otube cultures treated with AO alone (Figure 5, second panels from
the top), and dystrophin levels are increased further when AO/dan-
trolene or AO/Rycal ARM210 are used in combination (Figure 5,
lower two panels). Combination therapy also increased dystrophin
protein expression as measured by western blotting (Figure 6). TheseMolecular Therapy: Nucleic Acids Vol. 18 December 2019 581
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Figure 1. Human DMD Patient and Normal Control-Cell-Based Skeletal Muscle and Cardiomyocyte Models Used in This Study
(A) DMD copy number variation confirms DMD mutations in primary DMD patient-derived fibroblasts. A custom CGH array was used to identify DMD gene mutations and
breakpoint boundaries. Displayed are copy number data from individuals with a wild-type DMD gene (1002) or DMD patients with deletion spanning exons 46–51
(CDMD1003), 46–47 (CDMD1015), or exon 45 (CDMD1006). Probes within the deleted DMD region are highlighted in red. Tiled below are the genomic locations of the 79
DMD exons, with exon 1 beginning on the right and ending with exon 79 on the left. Patient fibroblasts were reprogrammed to iDRM or iPSC and subsequently differentiated
into skeletal or cardiac muscle lineage. (B) DMD iDRM-derived myotubes express RyR1, but not RyR2. Patient-derived iDRMs were differentiated to myotubes through
induced Myod activity and fusion conditions. Levels of RyR1 and Ryr2 expression were determined by RT-PCR in DMD iDRM CDMD1003- and CDMD1015-derived
myotubes relative to healthy control muscle biopsy or primary myoblasts (CDMD8006). (C) iPSC-derived skeletal muscles predominantly express RyR1, whereas iPSC-
derived cardiomyocytes predominantly express RyR2. DMD iPSC CDMD1003 and CDMD1006 or healthy control iPSC CDMD 1002 and 1006 were differentiated to my-
otubes or cardiomyocytes, and levels of RyR1 and RyR2 expression were determined using RT-PCR. CDMD8006 are healthy primary myoblasts. (D) Schematic representing
three patient mutations and strategies for exon skipping to restore reading frame. Mutations for patients CDMD1003 and CDMD1006 are indicated by dashed boxes (purple
and orange, respectively). The position of each primer pairs used for quantitating exon skipping are indicated outer primers for the first round of PCR and inner primers for the
second round of PCR. Location and coordinates for AO H44A and H45A are also indicated.
Molecular Therapy: Nucleic Acidsfindings demonstrate that observed increases in exon skipping trans-
late into increased dystrophin protein rescue, consistent with our
studies in mdx mice in vivo.20,21
Dantrolene Boosts AO Exon Skipping in iPSC-Derived
Cardiomyocytes
To assess the efficacy of AO/dantrolene combination treatment in
DMD cardiac cell models, we differentiated CDMD1003 iPSC23
into cardiomyocytes in culture. As shown in Figure 7, treatment of
CDMD1003 iPSC-derived cardiomyocytes with exon 45 skipping
AO leads to induction of skipped DMD mRNA at 200 nM (Figures
7A and 7B). When AO is used in combination with dantrolene,582 Molecular Therapy: Nucleic Acids Vol. 18 December 2019increased exon skipping activity is detectable at both 50-nM and
250-nM AO concentrations (Figure 7A). These findings extend the
observation that dantrolene can increase DMD exon skipping to
in vitro differentiated human DMD cardiomyocytes.
DISCUSSION
WhileDMD exon skipping AO have demonstrated substantial induc-
tion of dystrophin in animal models, only low levels of dystrophin
rescue have been documented in human clinical trials.18 While
even these low levels are plausibly slowing disease progression in skel-
etal muscle, greater dystrophin induction is predicted to yield better
efficacy. Therefore, alternate chemistries, delivery mechanisms, or
A B Figure 2. Dantrolene Boosts AO-Targeted Exon45
and Exon44 Skipping in Patient iDRM
(A and B) iDRM CDMD1003 (deletion of exons 46–51) (A)
or CDMD1015 (deletion of exon 45) (B) were differenti-
ated to myotubes and treated with AO targeting exon 45
skipping, H45A, with or without dantrolene, or dantrolene
alone. Skipped and unskipped mRNA products were
amplified using RT-PCR and quantified using an Agilent
2100 bioanalyzer. Data are expressed as normalized E45
or E44 skipping (skipped mRNA products over total
mRNA products). Bars represent SEM. *p < 0.05;
p values reflect a Student’s t test.
www.moleculartherapy.orgdrug combinations that better promote exon skipping could be of sig-
nificant value (for review see Barthélémy and Wein25).
We previously identified dantrolene as a skip booster in a drug screen
aimed at identifying compounds with the capacity to augment AO-
mediated DMD exon skipping in a reporter line.20 Dantrolene AO
skip-boosting activity has now been validated in mdx mice over
both long- and short-term systemic AO treatment. In these studies,
exon 23 AO/dantrolene combination therapy demonstrated higher
levels of exon 23-skipped mRNA and rescued dystrophin protein,
improved muscle function, and diminished pathophysiology relative
to those treated with AO or dantrolene alone.20,21
Dantrolene skip-boosting activity was further validated in patient
iDRM-derived myotubes amenable to restoration of reading frame by
exon 51 skipping, suggesting that boost activity of dantrolene may be
relevant to human DMD exon-skipping therapies in clinical trial and
being administered as a commercial product.20 Both 2-O-methyl and
morpholino AO were boosted by dantrolene. However, we have yet
to assess its activity in the context of alternate chemistries or AO target-
ing other DMD mutations currently in the therapeutic pipeline.26,27
Other compounds have been described with the ability to influence
skipping in DMD models.28–31 However, dantrolene is relatively
unique, as it is a potentially practical therapy to augment exon skip-
ping in humans, since it is an FDA-approved drug with a known
safety profile, broad usage in pediatrics, and some previous experi-
ence in treatment of DMD.32 Our new data further demonstrate
that dantrolene is able to augment exon skipping with AO targeting
at least three different AO different exons.
Here, we demonstrate that dantrolene can increase AO-mediated
skipping of exons 45 or 44, both of which are currently being targeted
in preclinical or clinical studies. When combined with exon 45- or
exon 44-skipping AO, dantrolene promotes exon skipping in rele-
vant DMD patient iPSC-/iDRM-derived myotubes. Similar results
are seen across cell models derived from two different exon 45
skip-amenable patients with distinct exon 45 mutations; deletion of
exons 46–51 ofDMD and deletion of exons 46–47 ofDMD. Likewise,
dantrolene boosts exon 44 skipping in patient-derived iDRM DMDmyotube cultures carrying a mutation amenable to reframing by
exon 44 skipping (deletion of exon 45 of DMD). While the degree
of boost is modest, it is in keeping with the levels boosted in mdx
mice that were previously shown to positively decrease disease pa-
thology and in keeping with the literature indicating that even low
levels of dystrophin can impact muscle function.18,21 Boost activity
is seen in both patient iDRM- and iPSC-derived myotube models,
adding confidence to our findings. Of note, differences in the robust-
ness of the differentiation into myotubes from iPSCs or iDRMs pro-
vided some variation in AO dosing. iPSC-derived myotubes were
more efficiently created in culture, and lower concentrations of AO
(100 nM) were required to induce AO or AO/dantrolene exon skip-
ping relative to iDRM (500 nM).
In skeletal muscle, dantrolene targets RyR1; a calcium channel
involved in the regulation of intracellular calcium release from the
sarcoplasmic reticulum during muscle contraction. In mdx mice,
RyR1has been shown to be nitrosylated, leading to leaky channels,33
and similar results have been seen in muscle biopsies from DMD
boys (A. Lacampagne, personal communication). For this reason,
dantrolene has been tested in a small cohort of eight boys over 2 years
in an attempt to control the leak and slow DMD progression.32
Consistent with studies in the mdx mouse, trends toward modest
reduction of serum creatine kinase (CK) and increased muscle func-
tion did not reach statistical significance. Nonetheless, no adverse ef-
fects of dantrolene treatment were observed in this DMD cohort,
aside from one patient in which dantrolene induced transient mus-
cle weakness,32 which was reversed upon lowering the dantrolene
dose by 25%. The patient received the lower dose for the study dura-
tion, highlighting the importance of monitoring potential acute
weakness due to dantrolene treatment. While we saw no effect of
dantrolene treatment alone on exon skipping or pathophysiology
in mdx,20,21 it remains possible that in humans dantrolene may
function alone to counter defective calcium regulation and down-
stream pathology in DMD, as suggested by others’ findings, as
well as a skip booster when co-administered with AO, and both ac-
tivities may slow disease progression.
Rycals regulate RyR activity by stabilizing calstabin:RyR binding
and have been reported to normalize leaky RyR Ca+ flux observedMolecular Therapy: Nucleic Acids Vol. 18 December 2019 583
Figure 3. Rycals ARM210 and S107 Boost AO-Directed Exon45 Skipping in Patient iDRM- and iPSC-Derived Myotubes
(A and B) iDRMCDMD1003 (deletion of exons 46–51) (A) or iPSCCDMD1003 (B) were differentiated to myotubes and treated with AO targeting exon 45 skipping, H45A, with
or without dantrolene, Rycal S107, or Rycal ARM210 or treated with drugs alone. Skipped and unskippedmRNA products were amplified using RT-PCR and quantified using
an Agilent 2100 bioanalyzer. Data are expressed as normalized E45 skipping (skipped mRNA products over total mRNA products). For each iDRM or iPSC, averages of two
independent experiments performed in triplicates (iDRM) or duplicates (iPSC) are shown. Bars represent SEM. *p < 0.05; p values reflect a Student’s t test. Dystrophin
immunostaining was performed using NCL-Dys1 (Dys1- rod domain) and NCL-Dys 2 (Dys 2- C-terminus) to measure the maturation of the myotubes. IgG control stainings
were also performed. Scale bars are 20 mm (C).
Molecular Therapy: Nucleic Acidsin mdx mouse muscle.33 For this reason, Rycal ARM210 has been
considered as a standalone therapy for DMD.24 We previously
demonstrated that Rycal S107 and ryanodine, like dantrolene,
also boost exon 51 AO skipping, leading us to hypothesize that
the RyR is the relevant dantrolene target for promoting exon skip-
ping.20 Here, we demonstrate that Rycals ARM210 and S107, like
dantrolene, both boost exon 45 or exon 44 AO-targeted exon skip-
ping, lending further support for skip regulation by a RyR-regu-
lated pathway and identifying a novel Rycal with potential for
boosting AO-mediated exon skipping in DMD. Because Rycals
act to stabilize a closed conformation rather than block the active
site, it has been suggested that they may not be limited by induced
muscle weakness, which can be observed at high dantrolene doses
in some patients.32–34 We have yet to determine the precise mech-
anism of RyR regulation of DMD exon skipping. However,
previous studies have elucidated a role for tissue-specific calcium584 Molecular Therapy: Nucleic Acids Vol. 18 December 2019regulation of alternative RNA splicing, providing a plausible mech-
anistic hypothesis to test in future studies.35,36 Thus, it may be that
leaky, nitrosylated RyR channels in DMD lead to high cytoplasmic
calcium, and dantrolene and both Rycals lead to a reduction of the
high calcium, leading to more efficient exon skipping.
Cardiac failure is a leading cause of death in DMD and thus is an
important target for effective therapies.5,37 Studies in mouse and
dog have indicated that AO exon-skipping treatments capable of
rescuing dystrophin in skeletal muscle do not rescue its expression
in cardiac tissue.14,38,39 The reason for this remains unclear, though
published data support the suggestion that both AO delivery to the
heart and limited skipping in cardiomyocytes limit the AO exon-
skipping efficacy in cardiac tissue.40 In the experiments presented
here, AO is artificially delivered to cardiomyocytes using oligofect-
amine, allowing us to examine the efficacy of AO/dantrolene boost
Figure 4. Rycal ARM210 and Dantrolene Boost AO-Mediated Exon44 RNA Skipping in Patient iDRM-Derived Myotubes
iDRM CDMD1015 (delta 45) were differentiated to myotubes and treated with AO targeting exon 44 skipping, H44A, with or without dantrolene or Rycal ARM210. Skipped
and unskipped mRNA products were amplified using RT-PCR and quantified using an Agilent 2100 bioanalyzer (A). Data are expressed as normalized E45 or E44 skipping
(mRNA skipped products over total mRNA products). Bars represent SEM. *p < 0.05; p values reflect a Student’s t test. Graphic represents two independent experiments run
as triplicate. iDRM CDMD1015 (deletion of exon 45) were differentiated to myotubes and treated with AO targeting exon 44 skipping, H44A, with or without dantrolene or
Rycal ARM210 and immunostaining for alpha-actinin (A-actinin) were performed to demonstrates maturation of the myotubes (B).
www.moleculartherapy.orgactivity in the context of cardiac muscle independently of delivery
considerations. Prior studies described dantrolene as specifically
targeting RyR1, expressed in skeletal, but not cardiac muscle.41
However, dantrolene has since been reported to also target RyR2,42
abundantly expressed in the heart and in our iPSC-derived cardio-
myocytes, and is likely the relevant target for dantrolene boost.
Notably, Rycals also will target both RyR1 and RyR2. It is widely sug-
gested that effective DMD treatment will rely on a drug cocktail, tar-
geting distinct aspects of DMD pathogenesis. Our findings highlight
unexpected effects of drug combinations and encourage consider-
ation of drug interactions and synergies in determining the ideal
cocktail for particular DMD patients.
MATERIALS AND METHODS
Collection, Isolation, and Propagation of Dermal Fibroblasts
Skin punches were obtained under institutional review board
(IRB)-approved protocol (#11-001087) with informed patient con-
sent, by coring a 3-mm diameter small piece of skin from the arm.
The entire skin punch was placed in sterile DMEM (phenol red
free; Thermo Fisher Scientific, Grand Island, NY, USA) + 1% peni-
cillin/streptomycin (Thermo Fisher Scientific, Grand Island, NY,
USA). Isolation of dermal fibroblasts was done as previously
described (Barthelemy et al.43). Fibroblast growth media was
changed every 3 days until 2–3 weeks, after which fibroblasts
were typically sub-confluent and transferred for expansion into a
T175 flask (Corning, Tewksbury, MA, USA). Each CDMD skin
punch is assigned a unique four-digit identifier, beginning with
CDMD1001 and subsequently increasing. Fibroblasts are consid-
ered as iDRMs once they are transduced with either LV-Myod-
ER(T) or LV-Puro-Myod-ER(T).Comparative Genomic Hybridization (CGH) Array Design and
Analysis
A custom 14,022 probe oligonucleotide array was designed with
probes tiling the DMD gene (Agilent, Santa Clara, CA, USA).
Genomic DNA was labeled with Cy3, and normal male genomic
DNA was labeled with Cy5 using a random priming kit (Agilent,
Santa Clara, CA, USA), and labeled DNA was co-hybridized to the
custom-designed array. Arrays were scanned with the DNA microar-
ray scanner with Surescan high-resolution technology (Agilent, Santa
Clara, CA, USA), and data were extracted with feature extraction soft-
ware version 10.5.1.1. The values were extracted from the software
and analyzed in R. Base-pair positions are reported relative to build
HG18, and the log ratio of the Cy3/Cy5 (test/normal) intensity is
plotted for all probes.
Myod1 Induction and Myotube Fusion of iDRM
iDRMs were seeded at 150,000 cells per well in fibroblast growth
media (DMEM [+ phenol red, high glucose] [Thermo Fisher
Scientific, Grand Island, NY, USA] + 15% fetal bovine serum
[FBS] [Omega Scientific, Tarzana, CA, USA] + 1% nonessential
amino acids [Thermo Fisher Scientific, Grand Island, NY,
USA] + 1% penicillin/streptomycin [Thermo Fisher Scientific,
Grand Island, NY, USA]) in 6-well plates (Corning, Tewksbury,
MA, USA) precoated for 1 h with 2.5 mL of 5 mg/mL laminin in
serum-free DMEM (BD Biosciences, San Jose, CA, USA). Myo-
blasts were seeded at 200,000 cells per well in skeletal muscle
cell growth media (Promocell, Heidelberg, Germany) + 15%
FBS + 1% penicillin/streptomycin in 6-well plates (Corning) pre-
coated for 1 h with 0.1% porcine gelatin (Sigma, St. Louis, MO,
USA). The following day, iDRMs were supplemented with 5 mMMolecular Therapy: Nucleic Acids Vol. 18 December 2019 585
Figure 5. Rycal ARM210 and Dantrolene Boost AO-
Mediated Exon44 Skipping in Patient iDRM-Derived
Myotubes to Induce Dystrophin Protein Expression
Dystrophin immunostaining was performed using NCL-
dys3 (Dys3, N-term), NCL-Dys1 (Dys1, rod domain), and
NCL-Dys 2 (Dys 2, C-term) antibodies. IgG control
staining were also performed. Scale bars represent
200 mm.
Molecular Therapy: Nucleic Acids4OH-tamoxifen (Sigma, St. Louis, MO, USA; dissolved in ethanol)
in fibroblast growth media for 24 h. On day 3, cells were washed in
1 PBS (Thermo Fisher Scientific), and fusion media containing
1 mM 4OH-tamoxifen was added (1:1 Ham’s F-10:DMEM [phenol
red free, high glucose], 2% horse serum [Thermo Fisher Scientific,
Grand Island, NY, USA], 2% insulin-transferrin-selenium)
(Thermo Fisher Scientific, Grand Island, NY, USA). Also, during
the first week of differentiation, we added SB431542 at a final con-
centration of 5 mM. Cells were kept for 2 weeks in fusion condi-
tions prior to treatment. Medium was changed every other day.
Collection of Primary Myoblasts and Differentiation
Primary myoblasts were obtained as previously described22 and
induced to differentiate for 15 days prior to collection.
Human-Induced Pluripotent Stem Cell Culture and
Differentiation
Human induced pluripotent stem cells (iPSCs) were reprogrammed
as previously published.23 They were grown on human embryonic
stem cells (hESC) qualified matrigel (Corning), fed daily with
mTeSR1 medium (Stem Cell Technologies, Vancouver, BC, Canada),
and passaged with 0.5 mM EDTA every 5–7 days. For differentiation
of iPSC-cardiomyocytes, confluent iPSCs were enzymatically dissoci-
ated to form aggregates and differentiated into the cardiomyocyte
lineage using the PSC cardiomyocyte differentiation kit (Thermo
Fisher Scientific, Grand Island, NY, USA). The medium was changed
every 2 days for 3 weeks. For immunohistochemistry, after transfec-
tion and drug treatments, cells were first split into single cells on
matrigel-coated coverslips and grown for 1 day prior to imaging.
For differentiation of hiPSC-derived skeletal muscle, cells were pro-
cessed as previously published.23 In brief, cells were committed to
the skeletal muscle lineage under the expression of a tamoxifen-
inducible estrogen receptor responsive to tamoxifen (Myod-ERT).
Following induction, the cells were differentiated in low-glucose
DMEM with 5% horse serum and 1 mM tamoxifen for 14 days prior
to treatment. Also, during the first 3 days of differentiation, we added586 Molecular Therapy: Nucleic Acids Vol. 18 December 2019SB431542 at a final concentration of 5 mM. Me-
dium was changed daily.
AO Transfection
On day 5 of differentiation (iDRM, iPSC-
derived skeletal muscle) or day 21 (iPSC-cardi-
omyocytes), cells were transfected with 0, 25, 50,
or 500 nM of 2-O-methyl AO targeting exon 45or exon 4413 (using oligofectamine; Thermo Fisher Scientific) trans-
fection reagent according to our previously published protocol.43
RNA Isolation, PCR, and Quantification
On the day of harvesting, cell pellets were scrapped directly in trizol
(Thermo Fisher Scientific) and total RNA isolated using the Purelink
RNAmini-kit (Thermo Fisher Scientific). For exon-skipping analysis,
200–500 ng of total RNA was reverse transcribed with an exon 54
gene-specific primer [20]. For cell lines eligible for exon 45 skipping,
a nested PCR was performed between DMD exons 43 and 52 using
previously described primers for cell line CDMD1003 [20,33] and
between DMD exons 43 and 50 for cell line CDMD 1006 (Ex42-o,
50-GTCCGTGAAGAAACGATGATG-30 + Ex50-o, 50-GTTTACCG
CCTTCCACTCAG-30 and Ex43-i, 50-TCTCTCCCAGCTTGATT
TCC-30 + Ex49-i, 50-CTGAGTGGCTGGTTTTTCCT-30). For cell
line CDMD1015, a nested PCR was performed between exons 42
and 46 (Ex42-o, 50-CAATGCTCCTGACCTCTGTGC-30 + Ex46-o,
50-GCTCTTTTCCAGGTTCAAGTGG-30 and Ex43-i, 50-GTCTA
CAACAAAGCTCAGGTCG-30 + Ex46-i, 50-GCAATGTTATCT
GCTTCCTCCAACC-30). The amplified products were run on the
Agilent 2100 bioanalyzer for exon-skipping quantification.
Compounds
All the drugs were prepared extemporaneously and re-suspended in
water. We used a commercially available formulation of dantrolene
(Revonto, Louisville, KY, USA) that is a formulation of dantrolene so-
dium (NDC: 27505-001-65) from DSM Pharmaceuticals. Rycal S107
and ARM210 were kindly provided by ARMGO Pharma.
Immunofluorescence
Cells were seeded at 40,000 cells per well on gelatin-coated 12-mm ster-
ile glass coverslips in 24-well plates. Cells were grown according to the
previously explained protocol.During all the procedures, cells were kept
at room temperature unless specified otherwise. After myotube forma-
tion, cells were fixed with acetone.23 Primary antibodies were incubated







Figure 6. Dantrolene Boosts the Induction of
Dystrophin Protein Expression in iDRM-Derived
Myotubes as Measured by Western Blotting
iDRM 1015 treated with AO H44A alone or in combina-
tion with dantrolene at 25 mM and immunoblotted using
NCL-dys antibody to detect dystrophin protein. iDRM
1002 (WT) was used as a dystrophin standard control
loaded in serial dilutions. GAPDH was used as loading
control (A). ImageJ was used to quantitate the western
blot results and are reported as values for Dystrophin
divided by GAPDH values (B).
www.moleculartherapy.orgGrove, IL, USA) at a dilution of 1:100 and alpha actinin (Sigma, St.
Louis, MO, USA) at a dilution of 1/250. Immunoglobulin G (IgG) con-
trols were also used: IgG1, ref 554121 (BD Biosciences, San Jose, CA,
USA), and IgG2A, ref 400202 (BioLegend, San Diego, CA, USA).
Secondary antibodies were used at a dilution of 1:500 (goat anti-
mouse IgG [SA5-10173] and goat anti-rabbit [35553]) from Thermo
Fisher Scientific for 1 h. Coverslips were mounted in ProLong gold
antifade with DAPI (Thermo Fisher Scientific). Images for were ac-
quired on a Zeiss AxioImager Z1microscope and with the AxioVision
rel. 4.6.3.0 acquisition software.BA
across two experiments are shown. iDRM CDMD1003 (deletion of exons 46–51) were differentiated to cardio
targeting exon 44 skipping, H44A, with or without dantrolene or Rycal ARM210.
Molecular TherapWestern Blot
Total cell lysates were resolved on 4%–12% bolt
protein gels by SDS-PAGE (Bolt Bis-Tris Plus
gels, Thermo Fisher Scientific) and transferred
to nitrocellulose membrane (Millipore). The
membrane was blocked for 1 h in 3% nonfat
dry milk in Tris-buffered saline (TBS) with
0.2% Tween 20 and incubated in primary anti-
bodies overnight at 4C. Incubation was per-
formed with the following primary antibodies:
dystrophin C-terminal (NCL-Dys1, 1:100,
Leica Biosystems) and glyceraldehyde 3-phos-
phate dehydrogenase (GAPDH) (MAB374,
1:50,000, Chemicon). Horseradish peroxidase-conjugated anti-rabbit IgG and anti-mouse IgG (GE Healthcare)
secondary antibodies were used at 1:15,000 dilutions in 3%
nonfat dry milk and incubated at room temperature (RT) for 2 h. Im-
munoblots were developed using enhanced chemiluminescence
(SuperSignal West Pico Chemiluminescent Substrate; Thermo Fisher
Scientific).
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